PINK:IDRSF

Idorsia Ag Stock News

> Biotechnology

Buy IDRSF

*Your capital is at risk

$5.75

+0 (+0%)

At Close: Jun 02, 2026

Idorsia: It's Time To Be Greedy (Technical Analysis)

09:48am, Friday, 11'th Nov 2022

Idorsia's stock is testing its most important overhead resistance and is trying to break out from its long-term downtrend, a rare situation that could lead to significant upside potential. The company

Idorsia Ltd (IDSRF) Q3 2022 Earnings Call Transcript

05:55pm, Friday, 28'th Oct 2022

Idorsia Ltd (OTC:IDSRF) Q3 2022 Results Conference Call October 25, 2022 8:00 AM ET Company Participants Andrew Weiss - IR Jean-Paul Clozel - CEO Simon Jose - Chief Commercial Officer André Muller -

Idorsia Ltd (IDRSF) CEO Jean-Paul Clozel on Q2 2022 Results - Earnings Call Transcript

03:36pm, Tuesday, 26'th Jul 2022

Idorsia Ltd (OTCPK:IDRSF) H1 2022 Earnings Conference Call July 26, 2022 8:00 AM ET Company Participants Jean-Paul Clozel - CEO André Muller - CFO Simon Jose - CCO Andrew Weiss - Head of IR Conferenc

Idorsia Is Likely Set For A Short Squeeze

01:15pm, Friday, 27'th May 2022

QUVIVIQ (Daridorexant) and PIVLAZ (Clazosentan) are now commercialized by Idorisa, and Johnson & Johnson is distributing Ponvory (Ponesimod). The Swiss and Canadian health authorities are supposed to

Idorsia: Positive Catalyst Coming Very Soon

05:29am, Thursday, 17'th Mar 2022

Idorsia: Positive Catalyst Coming Very Soon

Idorsia Ltd (IDRSF) CEO Jean-Paul Clozel on Q4 2021 Results - Earnings Call Transcript

02:08pm, Tuesday, 08'th Feb 2022

Idorsia Ltd (IDRSF) CEO Jean-Paul Clozel on Q4 2021 Results - Earnings Call Transcript

Idorsia: Heading Towards Profitability Faster Than Expected

05:22pm, Friday, 21'st Jan 2022

Idorsia's first product Daridorexant was approved by the FDA on January the 10th, 2022. Clazosentan just got approval in Japan on January the 20th, 2022.